Shedding light on some peer-reviewed randomized control trials conducted so far with this anti viral drug touted for use in alleviating intensive care in severe COVID-19 patients.

On May 22, 2020 the New England Journal of Medicine published a preliminary report of a double-blind randomized, placebo-controlled trial of intravenous remdesivir.

They concluded that remdesivir is superior to placebo in shortening recovery time in adults hospitalized with COVID-19. A total of 1063 patients underwent randomization.

On April 29, 2020 the Lancet published a double-blind randomized, placebo-controlled multicentre trial of intravenous remdesivir.

237 patients were studied, in which no statistically significant clinical benefit was ascertained, however a numerical reduction in time to clinical improvement was observed in hospitialized COVID-19 patients.

COVID19 numbers in India

This was the graph predicted by the Government of India towards the end of April 2020.
Impact of lockdown in different countries, with highlight on the direction it is moving.
The latest prediction which means, this is going to be quite a protracted course in India (Courtesy Rijo M John)

Questions remain in the manner in which the lockdown was implemented, one of, if not the harshest measure seen in the world. India went through a series of lockdowns, as it looked to beef up the healthcare system to cope with the expected growth of cases. At the time of initial observations of possible good containment, thanks to the early lockdown, the government clearly did not factor the impact of two major factors

  1. The reverse internal migration that has catapulted the first wave.
  2. The inevitable return of non resident Indians from all over the world sowing seeds of alarming growth

The biggest worry is, are we as a nation, ready to bear the brunt of this massive healthcare burden while trying to restore parity to remaining healthcare services as well as restoring some form of livelihood. Strong leadership is needed to withstand the storm, pandemics are opportunities for leaders to rise above all.

Bell Curve

India is currently into the third leg of battling COVID19. Apparently it should not be called a lockdown, because unlike the prior two, plenty of easing up is seen in restrictions with zonal divisions of the nation based on disease load.

The inept governance that GoI is known for under Modi means, the number of amendments and revisions of guidelines in itself need a large folder to sift through!

A graph that brought much muse to the scientific world is the prediction of how a bell shaped curve and dip in cases were projected into the third week of May. Whilst there is progressive ramping up of testing, and per million deaths continue to be one of the lowest in the world, this needed quite a stretch of imagination apart from its peculiar sync with the terminal date of the third leg of lockdown.

So what benefit does it serve in the midst of a pandemic, to undertest, under report and under diagnose COVID19? For all the sensationalism that this virus creates, it still has a very low mortality rate in comparison to its predecessors SARS and MERS.

Narendra Modi, all throughout his tenure as Prime Minister, always makes it a point to have his signature on every move. He prefers a distinctive path that centres all the actions as distinctly emanating from him.

It has been reported at large, how he sidelines every expert and we will have to just stand by and watch as things unfold perilously.

Currently we are in the rising phase of the curve. Unlike other countries, with better transparency indices than India, we are going to be having a persistent prolonged Bell curve in this pandemic.

The worry remains perennially on Indian healthcare workers as undertesting and under reporting would mean repeated exposures to viral loads, shortening the crippling healthcare system.

Create a website or blog at

Up ↑

%d bloggers like this: